Tag

Semaglutide

All articles tagged with #semaglutide

health1 day ago•3 min saved

GLP-1 Weight Drugs: Debunking the 'bones-shredding' myth

A viral claim that GLP-1 drugs like semaglutide (Ozempic) shred bones isn’t supported. A preliminary AAOS presentation linked GLP-1 use with higher rates of osteoporosis and osteomalacia, but the absolute numbers were small (about 4% and 2%), and weight loss itself may drive risk. Doctors advise monitoring bone health and preventive steps (calcium, vitamin D, strength training). Another study at the same conference suggested GLP-1s could reduce some postoperative complications in orthopedic patients. GLP-1s have GI side effects and potential eye risks, but their overall benefits for obesity and diabetes remain substantial; the key is weighing benefits against risks with a clinician and avoiding sensational myths.

via Gizmodo|

#bone-health #glp-1s #health

health18 days ago•2 min saved

Stopping GLP-1 Drugs Sparks Quick Loss of Heart-Protection Benefits

A BMJ Medicine analysis of about 333,000 adults with diabetes found that consistent GLP-1 use lowers cardiovascular risk by 18% over three years, but stopping for as little as six months can raise risk by up to 8%, and pausing for one to two years can increase risk by roughly 22%, erasing the drug’s protection. Weight regain and a rebound in inflammation, blood pressure, and cholesterol accompany interruptions, which can leave a lasting “metabolic whiplash.” With many patients stopping or pausing due to cost, side effects, or shortages, the findings underscore the importance of maintaining GLP-1 therapy where possible.

via Futurism|

#cardiovascular-risk #diabetes #glp-1

health22 days ago•3 min saved

FDA Clears Higher-Dose Wegovy to Boost Weight Loss

The FDA approved Wegovy HD, a 7.2 mg weekly dose of semaglutide, a higher-dose version expected to boost weight loss. In trials, the higher dose yielded about 19% body-weight loss (roughly 47 lb) vs 16% (about 39 lb) with the 2.4 mg dose over about 17 months; the drug will be available in April with price to be announced. European regulators had approved it earlier. Side effects were common (GI issues in 70%+; 23% reported skin sensations) and serious adverse events occurred in ~7% of the higher-dose group. The jump from 2.4 mg to 7.2 mg is substantial, and real-world safety will need monitoring. An oral Wegovy pill was approved by the FDA in December for context.

via ScienceAlert|

#fda #health #obesity-drug

health22 days ago•2 min saved

FDA approves Wegovy HD, a higher-dose weight-loss option under a national priority program

The FDA cleared Wegovy HD (7.2 mg) for weight loss and long-term maintenance in adults with obesity or overweight plus a weight-related condition, marking the fourth approval under the Commissioner’s National Priority Voucher program. The higher dose yielded greater average weight loss with a safety profile consistent with prior semaglutide doses, though GI side effects were common and there is a boxed warning for thyroid C-cell tumors; the approval was granted to Novo Nordisk, and a June public hearing on the voucher program is planned.

via fda.gov|

#fda #health #national-priority-voucher

health23 days ago•14 min saved

FDA clears higher-dose Wegovy injections for obesity treatment

The FDA has approved a higher-dose Wegovy (semaglutide) injectable for obesity treatment, expanding weekly dosing options to help with weight management amid ongoing efforts to address obesity-related health risks.

via AP News|

#fda #health #obesity

health23 days ago•3 min saved

GLP-1 Weight-Loss Drugs Linked to Lower Depression and Anxiety Risks in Large Study

A Lancet Psychiatry study of more than 95,000 patients using GLP-1 diabetes/weight‑loss medications (notably semaglutide) found substantially lower risks of worsening mental illness, depression, anxiety, substance-use disorders, self-harm, and related hospital care. While the results suggest a potential mental-health benefit, the study is observational and cannot establish causality; clinical trials are needed to determine if the drugs themselves improve mental health beyond weight loss.

via Euronews.com|

#diabetes #glp-1 #health

health23 days ago•4 min saved

Heart Risk Surges Within Months of Quitting GLP-1 Diabetes Drugs

A large VA study found that staying on GLP-1 medications (such as semaglutide) for at least two years lowers major cardiovascular events by about 18% versus controls, but stopping the therapy leads to a rapid rebound in risk within six months—worsened by cost, side effects, and access barriers—highlighting the need for long-term maintenance and affordable access to these drugs.

via Gizmodo|

#cardiovascular-disease #glp-1s #health

science23 days ago•5 min saved

Wegovy May Elevate Rare Eye Stroke Risk, Study Finds

A large look at FDA adverse-event data suggests Wegovy (high-dose semaglutide) has a rare link to NAION, an “eye stroke” that can cause sudden vision loss, with men at higher risk than women. Wegovy shows a stronger association than Ozempic, possibly due to rapid weight loss and blood‑pressure fluctuations, but the overall risk remains very small and more research is needed.

via ScienceAlert|

#eye-stroke #naion #science

health23 days ago•3 min saved

GLP-1 diabetes meds may curb worsening anxiety and depression, study finds

A large Swedish study of about 95,000 people with depression or anxiety who were taking diabetes medications found that GLP-1 receptor agonists—especially semaglutide and liraglutide—were associated with a lower risk of worsening mental health outcomes such as hospitalizations, sick leave, self-harm, or death, while other GLP-1 drugs did not show the same benefit; experts caution about drawing causality from observational data. A separate Danish study linked first-trimester exposure to semaglutide or liraglutide for diabetes with a higher risk of preterm birth.

via The Guardian|

#anxiety #depression #glp-1-receptor-agonists

health25 days ago•5 min saved

Most weight lost on GLP-1 obesity drugs returns within a year, study finds

A meta-analysis of six randomized trials (3,200+ participants) shows people rapidly regain about 60% of the weight lost during GLP-1 class obesity treatments within a year of stopping, with long-term modelling suggesting regain may plateau after around 60 weeks and reach roughly 75% of the lost weight. The studies raise uncertainty about whether regained weight is lean mass or fat, and they underscore the potential need for tapering doses and lifestyle support to preserve fat loss after cessation.

via ScienceAlert|

#glp-1 #health #obesity-drugs

science1 month ago•11 min saved

Sex-Specific GLP-1 Brain Map Could Explain Weight-Loss Drug Differences

Researchers used RNAscope to build the first sex-specific atlas of GLP-1 expression in the mouse brain, mapping GLP-1 across 25 brain nuclei in three female and three male mice. They found notable sex differences: females have higher GLP-1 density in hindbrain appetite regions (ROb, SolV, SolM), while males show higher GLP-1 in the olfactory bulb, with some regions showing female-only (ventral tegmental area) or male-only (lateral hypothalamus) expression. The atlas helps explain why women often lose more weight on GLP-1 drugs like semaglutide and suggests potential sex-specific avenues for treating addiction, depression, and cognitive decline, though limitations include the small sample size and the fact that transcript presence does not prove peptide release or function.

via Neuroscience News|

#brain-atlas #glp-1 #obesity

health1 month ago•3 min saved

Study ties high-dose Wegovy to fivefold eye-stroke risk versus Ozempic

A study of FDA adverse-event reports (2017–2024) found Wegovy’s high-dose semaglutide for obesity linked to about five times the risk of non-arteritic anterior ischemic optic neuropathy (NAION) compared with Ozempic’s diabetes-dose semaglutide, with men at higher risk than women. Rybelsus and tirzepatide showed no increased risk. The findings are observational and do not prove causation; NAION is rare (roughly 1 in 10,000 on semaglutide). Regulators have issued warnings and Novo Nordisk says the overall benefit–risk profile remains favorable while continuing safety monitoring.

via The Guardian|

#adverse-event-reporting #health #naion

health1 month ago•133 min saved

After stopping GLP-1 drugs: UK study tracks patients for a year

UK researchers followed patients for a year after stopping GLP-1 receptor agonists (such as semaglutide-based Ozempic/Wegovy) to observe outcomes and inform understanding of discontinuation effects on weight and metabolic health.

via theprint.in|

#discontinuation #glp-1 #health

health1 month ago•6 min saved

GLP-1 Diabetes Drugs May Cut Addiction Risk, Large VA Study Suggests

A BMJ study using electronic health records from over 600,000 US veterans found that starting GLP-1 drugs (such as semaglutide/Ozempic, liraglutide, and tirzepatide) was associated with a 14% lower risk of developing a new substance-use disorder, and among those with existing disorders, a 26% reduction in substance-related hospital admissions, a 39% drop in overdoses, and a 50% decrease in deaths over three years. The study used an observational approach with target-trial emulation, so it shows associations rather than proven causation, and results may not generalize beyond an older, predominantly male veteran population. Randomized controlled trials are needed to confirm causality and applicability to broader groups.

via ScienceAlert|

#addiction #glp-1 #health

health1 month ago•3 min saved

Two-Drug Weight-Loss Approach Shows Promise; GLP-1 Drug Plus Muscle-Builder Outperforms Alone

In a phase II trial of about 500 adults with obesity, adding the muscle-preserving antibody bimagrumab to the GLP-1 drug semaglutide produced greater weight and fat loss and less lean-mass loss than semaglutide alone over 48 weeks (with Week 72 data showing continued fat-loss advantage and lean-mass preservation). Safety was in line with known profiles. If confirmed, this combo could represent a new obesity treatment avenue, though traditional strategies like resistance training and adequate protein intake remain important for preserving muscle during weight loss.

via Gizmodo|

#bimagrumab #glp-1 #health